Bangemann K, Schulz W, Wohlleben J, Weyergraf A, Snitjer I, Werfel T, Schmid-Ott G, Böhm D
Institut für Innovative Rehabilitation, Krankenhaus-Management und Stressmedizin (IREHA) der Lielje Gruppe in Löhne bei Bad Oeynhausen, Bad Oeynhausen, Deutschland.
Hautarzt. 2014 Dec;65(12):1056-61. doi: 10.1007/s00105-014-3513-9.
Psoriasis is associated with higher risk for depression and anxiety disorders. Yet the complex system linking disease symptoms with physical and mental outcomes is poorly understood.
The central aim of this study was to identify physical, psychological, and social factors that exacerbate or protect against the perception of symptoms of depression and anxiety among individuals starting in-patient treatment for psoriasis. Another aim was to investigate if improved clinical status of the psoriasis is associated with improved psychological and physical wellbeing one year after treatment.
In this follow-up study a sample of 381 psoriasis in-patients in Germany were questioned before starting treatment and one year after treatment (166 participants) using instruments to measure socioeconomic variables, perceived somatic severity, life quality (DLQI, SF-8), feelings of stigmatization (QES), and depression and anxiety (HADS-D). Coping (Trier Coping Scale) and pathological worry (PSWQ-PW) were also measured at the initial time point. Multiple regression analyses of variance for repeated measurements and of correlation were conducted.
Self-reported symptoms of anxiety and depression were higher than in normal populations. Perceived severity of physical symptoms was not correlated with depression or anxiety at the initial time point. The strongest predictors of depression and anxiety in our sample were measures of life quality. Life quality was predicted in a large part by stigmatization. Increased momentary symptom severity and increased perceived discomfort over time was not associated with increased perception of symptoms of depression.
Our findings extend previous research on the importance of stigmatization for quality of life to the specific outcome of depression and anxiety. It confirms the desirability of early screening of psoriasis patients for depression and anxiety and initiating treatment by a qualified therapist.
银屑病与抑郁和焦虑症的较高风险相关。然而,将疾病症状与身心结果联系起来的复杂系统却鲜为人知。
本研究的主要目的是确定在开始接受银屑病住院治疗的个体中,加剧或预防抑郁和焦虑症状感知的身体、心理和社会因素。另一个目的是调查银屑病临床状况的改善是否与治疗一年后的心理和身体健康改善相关。
在这项随访研究中,对德国381名银屑病住院患者在开始治疗前和治疗一年后(166名参与者)进行了询问,使用工具测量社会经济变量、感知到的躯体严重程度、生活质量(皮肤病生活质量指数、SF-8)、耻辱感(耻辱感量表)以及抑郁和焦虑(医院焦虑抑郁量表-抑郁分量表)。在初始时间点还测量了应对方式(特里尔应对量表)和病理性担忧(宾夕法尼亚大学忧虑问卷-病理性担忧分量表)。进行了重复测量的多元回归方差分析和相关性分析。
自我报告的焦虑和抑郁症状高于正常人群。在初始时间点,感知到的身体症状严重程度与抑郁或焦虑无关。我们样本中抑郁和焦虑的最强预测因素是生活质量指标。生活质量在很大程度上由耻辱感预测。随着时间的推移,瞬间症状严重程度的增加和感知到的不适感增加与抑郁症状感知的增加无关。
我们的研究结果将先前关于耻辱感对生活质量重要性的研究扩展到抑郁和焦虑这一特定结果。它证实了对银屑病患者进行抑郁和焦虑早期筛查并由合格治疗师启动治疗的必要性。